<code id='98B200AA38'></code><style id='98B200AA38'></style>
    • <acronym id='98B200AA38'></acronym>
      <center id='98B200AA38'><center id='98B200AA38'><tfoot id='98B200AA38'></tfoot></center><abbr id='98B200AA38'><dir id='98B200AA38'><tfoot id='98B200AA38'></tfoot><noframes id='98B200AA38'>

    • <optgroup id='98B200AA38'><strike id='98B200AA38'><sup id='98B200AA38'></sup></strike><code id='98B200AA38'></code></optgroup>
        1. <b id='98B200AA38'><label id='98B200AA38'><select id='98B200AA38'><dt id='98B200AA38'><span id='98B200AA38'></span></dt></select></label></b><u id='98B200AA38'></u>
          <i id='98B200AA38'><strike id='98B200AA38'><tt id='98B200AA38'><pre id='98B200AA38'></pre></tt></strike></i>

          Home / entertainment / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:7187

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In